Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

Presentation iASSESS 2017

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in those Undergoing PCI

Presenter: Sripal Bangalore

August 30, 2017

Presentation TCT 2014

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in Those Undergoing PCI

Presenter: Frederick Feit, Sripal Bangalore

September 13, 2014

Presentation TCT 2014

Are GP IIb/IIIa Inhibitors Still Useful?

Presenter: Marco Valgimigli

September 13, 2014

$Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial$

Presentation EuroPCR 2014

Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial

Presenter: Uwe Zeymer

May 21, 2014

Presentation TCT 2013

Locally Applied Intralesional GP IIb/IIIa Inhibitors Are the Method of Choice!

Presenter: Sameer Mehta

October 31, 2013

Presentation TCT 2013

Antithrombin Therapy (GP IIb/IIIa inhibitors) in Patients with ACS and Those Undergoing PCI

Presenter: Sripal Bangalore

October 27, 2013

$Unfractionated, Low Molecular Weight Heparins, and Xa Inhibitors in ACS and PCI, With and Without GP IIb/IIIa Inhibitors$

Presentation Fellows 2012

Unfractionated, Low Molecular Weight Heparins, and Xa Inhibitors in ACS and PCI, With and Without GP IIb/IIIa Inhibitors

Presenter: George Dangas

April 22, 2012

Advertisement

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in those Undergoing PCI

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in Those Undergoing PCI

Are GP IIb/IIIa Inhibitors Still Useful?

Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial

Locally Applied Intralesional GP IIb/IIIa Inhibitors Are the Method of Choice!

Antithrombin Therapy (GP IIb/IIIa inhibitors) in Patients with ACS and Those Undergoing PCI

Unfractionated, Low Molecular Weight Heparins, and Xa Inhibitors in ACS and PCI, With and Without GP IIb/IIIa Inhibitors

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content